# PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

> **NCT07175480** · PHASE2 · RECRUITING · sponsor: **Jinling Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Metastatic Renal Cell Carcinoma (mRCC)

## Interventions

- **DRUG:** Intermittent PD-1/PD-L1 ICI + VEGFR-TKI

## Key facts

- **NCT ID:** NCT07175480
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2027-08
- **Final completion:** 2030-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07175480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07175480, "PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07175480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*